|
RAB30 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.22220000032503E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.06069999999503E-05 |
| Normal-vs-Stage2 |
1.166350E-04 |
| Normal-vs-Stage3 |
2.35860000419308E-08 |
| Normal-vs-Stage4 |
8.16490000055126E-08 |
| Stage1-vs-Stage2 |
6.601000E-01 |
| Stage1-vs-Stage3 |
6.238100E-04 |
| Stage1-vs-Stage4 |
8.100500E-03 |
| Stage2-vs-Stage3 |
1.234610E-01 |
| Stage2-vs-Stage4 |
1.686370E-01 |
| Stage3-vs-Stage4 |
9.443800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11089999998981E-06 |
| Normal-vs-AfricanAmerican |
2.7696000000077E-06 |
| Normal-vs-Asian |
2.27250000000012E-05 |
| Caucasian-vs-AfricanAmerican |
5.784200E-01 |
| Caucasian-vs-Asian |
8.924000E-01 |
| AfricanAmerican-vs-Asian |
6.242600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.0752000025951E-08 |
| Normal-vs-Female |
2.94199999995026E-06 |
| Male-vs-Female |
3.449900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.72730000000243E-05 |
| Normal-vs-Age(41-60Yrs) |
2.56630000028402E-07 |
| Normal-vs-Age(61-80Yrs) |
4.83060000000535E-07 |
| Normal-vs-Age(81-100Yrs) |
6.390400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.167900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.141900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.926400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.850400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.761400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.506400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.05559999999494E-05 |
| Classical-VS-Follicular |
5.955600E-01 |
| Classical-VS-Other |
1.275590E-01 |
| Classical-VS-Normal |
1.52981000000052E-05 |
| Tall-VS-Follicular |
2.181400E-03 |
| Tall-VS-Other |
9.442400E-01 |
| Tall-VS-Normal |
8.99920027386258E-10 |
| Follicular-VS-Other |
2.341000E-01 |
| Follicular-VS-Normal |
1.69079999999822E-05 |
| Other-VS-Normal |
8.41759999999914E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.53940000002795E-06 |
| Normal-vs-N1 |
4.92599999679655E-08 |
| N0-vs-N1 |
8.188300E-02 |
|
|
